Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV‐50717) Compared With Tetrabenazine in Healthy Volunteers-Reference-Cited by-同舟云学术

Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV‐50717) Compared With Tetrabenazine in Healthy Volunteers

Published:2020-03-10 Issue:4 Volume:13 Page:707-717
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clin Transl Sci

Author:

Schneider Frank¹,Bradbury Margaret²,Baillie Thomas A.³,Stamler David²,Hellriegel Edward⁴,Cox Donna S.⁵,Loupe Pippa S.⁶,Savola Juha‐Matti⁷,Rabinovich‐Guilatt Laura⁸

Affiliation:

1. Teva Pharmaceutical Industries, Ratiopharm GmbH Ulm Germany

2. Formerly of Teva Pharmaceuticals Alterity Therapeutics Limited Newark California USA

3. Department of Medicinal Chemistry School of Pharmacy University of Washington Seattle Washington USA

4. Teva Pharmaceutical Products R&D, Inc. West Chester Pennsylvania USA

5. Formerly of Teva Pharmaceuticals Pfizer Corporation Norristown Pennsylvania USA

6. Teva Pharmaceuticals Industries New Orleans Louisiana USA

7. Teva Pharmaceuticals International GmbH Basel Switzerland

8. Teva Pharmaceutical Industries Netanya Israel

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12754

Reference20 articles.

1. Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial

2. Tetrabenazine in the treatment of Huntington's disease;Paleacu D.;Neuropsychiatr. Dis. Treat.,2007

3. Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors

4. Tetrabenazine-induced depletion of brain monoamines: Characterization and interaction with selected antidepressants

5. Tetrabenazine (Xenazine), an FDA‐approved treatment option for Huntington's disease‐related chorea;Yero T.;P T,2008

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Profiling deutetrabenazine extended-release tablets for tardive dyskinesia and chorea associated with Huntington’s disease;Expert Review of Neurotherapeutics;2024-07-09

2. 2023 White Paper on Recent Issues in Bioanalysis: Deuterated Drugs; LNP; Tumor/FFPE Biopsy; Targeted Proteomics; Small Molecule Covalent Inhibitors; Chiral Bioanalysis; Remote Regulatory Assessments; Sample Reconciliation/Chain of Custody (PART 1A – Recommendations on Mass Spectrometry, Chromatography, Sample Preparation Latest Developments, Challenges, and Solutions and BMV/Regulated Bioanalysis PART 1B - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV, Biomarkers/IVD/CDx/BAV, Immunogenicity, Gene & Cell Therapy and Vaccine);Bioanalysis;2024-05-02

3. A Bioequivalence Comparison Between the Once‐Daily Extended‐Release Tablet and the Twice‐Daily Tablet Formulations of Deutetrabenazine at Steady State;Clinical Pharmacology in Drug Development;2024-01-12

4. Prodrugs as empowering tools in drug discovery and development: recent strategic applications of drug delivery solutions to mitigate challenges associated with lead compounds and drug candidates;Chemical Society Reviews;2024

5. Electrochemical Mono-Deuterodefluorination of Trifluoromethyl Aromatic Compounds with Deuterium Oxide;CCS Chemistry;2024-01